Sensorion SA (ALSEN) - Total Assets
Based on the latest financial reports, Sensorion SA (ALSEN) holds total assets worth €73.34 Million EUR (≈ $85.74 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Sensorion SA debt service capacity to assess how comfortably operating cash covers total debt obligations.
Sensorion SA - Total Assets Trend (2011–2024)
This chart illustrates how Sensorion SA's total assets have evolved over time, based on quarterly financial data. See ALSEN book value for net asset value and shareholders' equity analysis.
Sensorion SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Sensorion SA's total assets of €73.34 Million consist of 96.0% current assets and 4.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €51.96 Million | 74.8% |
| Accounts Receivable | €376.00K | 0.4% |
| Inventory | €-376.00K | -0.4% |
| Property, Plant & Equipment | €2.71 Million | 3.0% |
| Intangible Assets | €746.00K | 0.8% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Sensorion SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Sensorion SA market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sensorion SA's current assets represent 96.0% of total assets in 2024, a decrease from 98.0% in 2011.
- Cash Position: Cash and equivalents constituted 74.8% of total assets in 2024, up from 42.8% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is cash and equivalents at 74.8% of total assets.
Sensorion SA Competitors by Total Assets
Key competitors of Sensorion SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Sensorion SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.90 | 6.92 | 8.82 |
| Quick Ratio | 4.90 | 7.52 | 8.82 |
| Cash Ratio | 0.00 | 5.31 | 1.62 |
| Working Capital | €55.63 Million | €83.82 Million | €28.99 Million |
Sensorion SA - Advanced Valuation Insights
This section examines the relationship between Sensorion SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.05 |
| Latest Market Cap to Assets Ratio | 1.86 |
| Asset Growth Rate (YoY) | 92.0% |
| Total Assets | €89.28 Million |
| Market Capitalization | $166.23 Million USD |
Valuation Analysis
Above Book Valuation: The market values Sensorion SA's assets above their book value (1.86x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Sensorion SA's assets grew by 92.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sensorion SA (2011–2024)
The table below shows the annual total assets of Sensorion SA from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €89.28 Million ≈ $104.37 Million |
+91.98% |
| 2023-12-31 | €46.50 Million ≈ $54.37 Million |
+19.45% |
| 2022-12-31 | €38.93 Million ≈ $45.51 Million |
-34.03% |
| 2021-12-31 | €59.02 Million ≈ $69.00 Million |
-13.05% |
| 2020-12-31 | €67.87 Million ≈ $79.35 Million |
+78.17% |
| 2019-12-31 | €38.09 Million ≈ $44.53 Million |
+302.37% |
| 2018-12-31 | €9.47 Million ≈ $11.07 Million |
-15.18% |
| 2017-12-31 | €11.16 Million ≈ $13.05 Million |
-5.83% |
| 2016-12-31 | €11.85 Million ≈ $13.86 Million |
-28.26% |
| 2015-12-31 | €16.52 Million ≈ $19.31 Million |
+653.59% |
| 2014-12-31 | €2.19 Million ≈ $2.56 Million |
+93.56% |
| 2013-12-31 | €1.13 Million ≈ $1.32 Million |
+199.04% |
| 2012-12-31 | €378.72K ≈ $442.76K |
+24.98% |
| 2011-12-31 | €303.01K ≈ $354.26K |
-- |
About Sensorion SA
Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. The company's product portfolio includes SENS-401 SSNHL, which has completed Phase 2b clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2a clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, whi… Read more